Neuroscience
- Business Wire
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F…
Read More » - Business
Takeda Completes Sale of Its Japan Consumer Health Care Business Unit to Blackstone
Osaka, Japan: Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - Health
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and…
Read More » - Business
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Osaka, Japan & Cambridge, Mass., United States: Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit…
Read More » - Business
Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio
Osaka, Japan & Brisbane, Calif., United States: Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active…
Read More » - Business
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
Osaka, Japan: FY2020 Q3 Year-to-Date Results Driven by 15% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO +24.0%, TAKHZYRO…
Read More » -
Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…
Read More » - United States
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Osaka, Japan & Cambridge, Mass., United States: Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access…
Read More » - Business
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
Osaka, Japan & Cambridge, Mass., United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More » - Health
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
Osaka, Japan: Three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW) to…
Read More » - Technology
Takeda Accelerates Digital Transformation with Accenture and AWS
Osaka, Japan & Seattle, New York, United States: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and…
Read More » - Health
Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis
Osaka, Japan: Interim analysis from VISIBLE OLE study showed long-term findings consistent with the known safety profile of vedolizumab with…
Read More » - United States
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Japan & United States: − Potential first-in-class therapy designed to treat the underlying cause of liver disease associated…
Read More »